My NCBI | Sign In
RSS Settings
  • Search: Negredo Eugenia[au]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 55

    1.

    Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6 Years on Nevirapine.

    Rodríguez-Arrondo F, Aguirrebengoa K, Portu J, Muñoz J, García MA, Goikoetxea J, Martínez E, Iribarren JA, Perez-Alvarez N, Negredo E, Clotet B.

    Curr HIV Res. 2009 Sep;7(5):526-532.PMID: 19925403 [PubMed - as supplied by publisher]Related articles

    2.

    Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia.

    Garrabou G, Morén C, Gallego-Escuredo JM, Milinkovic A, Villarroya F, Negredo E, Giralt M, Vidal F, Pedrol E, Martínez E, Cardellach F, Gatell JM, Miró O.

    J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):443-51.PMID: 19779356 [PubMed - in process]Related articles

    3.

    Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

    Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B; MULTINEKA Study Group.

    Clin Infect Dis. 2009 Sep 15;49(6):892-900.PMID: 19663689 [PubMed - indexed for MEDLINE]Related articles

    4.

    Disorders of body fat distribution in HIV-1-infected patients.

    Moreno S, Miralles C, Negredo E, Domingo P, Estrada V, Gutiérrez F, Lozano F, Martínez E.

    AIDS Rev. 2009 Jul-Sep;11(3):126-34. Review.PMID: 19654854 [PubMed - indexed for MEDLINE]Related articles

    5.

    The changing face of HIV/AIDS in treated patients.

    Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B.

    Curr HIV Res. 2009 Jul;7(4):365-77. Review.PMID: 19601771 [PubMed - indexed for MEDLINE]Related articles

    6.

    Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.

    Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, González-García M, Moltó J, Negredo E, Clotet B.

    AIDS Rev. 2009 Apr-Jun;11(2):103-9. Review.PMID: 19529750 [PubMed - indexed for MEDLINE]Related articles

    7.

    Low levels of adherence to antiretroviral therapy in HIV-1-infected women with menstrual disorders.

    Fumaz CR, Muñoz-Moreno JA, Ferrer MJ, Negredo E, Pérez-Alvarez N, Tarrats A, Clotet B.

    AIDS Patient Care STDS. 2009 Jun;23(6):463-8.PMID: 19519230 [PubMed - indexed for MEDLINE]Related articles

    8.

    Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy.

    Negredo E, Puig J, Aldea D, Medina M, Estany C, Pérez-Alvarez N, Rodríguez-Fumaz C, Muñoz-Moreno JA, Higueras C, Gonzalez-Mestre V, Clotet B.

    AIDS Res Hum Retroviruses. 2009 Apr;25(4):451-5.PMID: 19320569 [PubMed - indexed for MEDLINE]Related articles

    9.

    Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.

    Moltó J, Llibre JM, Ribera E, Mínguez C, del Río JS, Pedrol E, Vallecillo G, Cedeño S, Valle M, Miranda C, Negredo E, Clotet B; SQV-HEP Study Group.

    J Antimicrob Chemother. 2009 May;63(5):992-7. Epub 2009 Mar 11.PMID: 19279052 [PubMed - indexed for MEDLINE]Related articles

    10.

    Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

    Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.

    Antimicrob Agents Chemother. 2009 May;53(5):1937-43. Epub 2009 Mar 9.PMID: 19273671 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.

    Harris M, Côté H, Ochoa C, Allavena C, Negredo E, Thorne A, Cahn P, Zala C, Raffi F, Clotet B, Singer J, Montaner J; CTN 177 Study Team.

    J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):335-7. No abstract available. PMID: 19242263 [PubMed - indexed for MEDLINE]Related articles

    12.

    Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.

    Podzamczer D, Olmo M, Sanz J, Boix V, Negredo E, Knobel H, Domingo P, Pineda JA, Vilades C, Quero JH, Force L, Lahoz JG, Muñoz P, Llibre JM, Mariño A, Ortega E, Dalmau D, Gatell JM, Antón E, Sola J, Galindo MJ, Pedrol E, Sanz J, Lima JT, Flores J; NODy Study Group.

    J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):390-6.PMID: 19214120 [PubMed - indexed for MEDLINE]Related articles

    13.

    Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients.

    Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, Pérez-Alvarez N, Moltó J, Gómez G, Clotet B.

    AIDS Res Hum Retroviruses. 2008 Oct;24(10):1301-7.PMID: 18844464 [PubMed - indexed for MEDLINE]Related articles

    14.

    Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.

    Moltó J, Barbanoj MJ, Miranda C, Blanco A, Santos JR, Negredo E, Costa J, Domingo P, Clotet B, Valle M.

    Clin Pharmacokinet. 2008;47(10):681-92.PMID: 18783298 [PubMed - indexed for MEDLINE]Related articles

    15.

    Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.

    Moltó J, Valle M, Miranda C, Cedeño S, Miranda J, Santos JR, Negredo E, Vilaró J, Costa J, Clotet B.

    J Antimicrob Chemother. 2008 Oct;62(4):784-92. Epub 2008 Jun 30.PMID: 18593723 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.

    Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet B.

    Antivir Ther. 2008;13(2):231-40. Erratum in: Antivir Ther. 2008;13(3):467. PMID: 18505174 [PubMed - indexed for MEDLINE]Related articles

    17.

    Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.

    Negredo E, Puigdomènech I, Marfil S, Puig J, Pérez-Alvarez N, Ruiz L, Rey-Joly C, Clotet B, Blanco J.

    J Antimicrob Chemother. 2008 Feb;61(2):400-4. Epub 2007 Dec 14.PMID: 18083750 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study.

    Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, Tuldrà A, Rovira T, Viladrich C, Bayés R, Burger DM, Negredo E, Clotet B; SERAD Validation Team.

    AIDS Res Hum Retroviruses. 2007 Oct;23(10):1166-75.PMID: 17961100 [PubMed - indexed for MEDLINE]Related articles

    19.

    Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.

    Pruvost A, Théodoro F, Agrofoglio L, Negredo E, Bénech H.

    J Mass Spectrom. 2008 Feb;43(2):224-33.PMID: 17935070 [PubMed - indexed for MEDLINE]Related articles

    20.

    Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

    Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.

    Ther Drug Monit. 2007 Oct;29(5):648-51.PMID: 17898658 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    2 free full-text articles in PubMed Central

    Find related data

    Search details

    » See more...

    Recent activity